Ganitumab for the treatment of small-cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 23, Issue 10, 2014, Pages 1423-1432

  Martínez, Pablo ^a   Sales Fidalgo, Paula Alexandra ^b   Felip, Enriqueta ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

Author keywords

Ganitumab; IGF receptor; Insulin; Small cell lung cancer

Indexed keywords

GANITUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOID; COLORECTAL CARCINOMA; HUMAN; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS CARCINOMA; SARCOMA; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; TREATMENT INDICATION; ANIMAL; CANCER STAGING; DISEASE COURSE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTOR, IGF TYPE 1; SMALL CELL LUNG CARCINOMA;

EID: 84907062270     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.951434     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
2. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2(12):1067-77
3. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17(6):1794-801
4. Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987;5(9):1401-9
5. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17(8):2300-8
6. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23(16):3752-9
7. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987;5(12):1864-73
8. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol 2007;19(2):103-8
9. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91(2):151-6
10. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21(3):215-44
11. Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14(20):6364-70
12. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3(5):298-302
13. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005;65(22):10123-7
14. Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66(20):10100-11
15. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94(4):465-8
16. Zhang X, Kamaraju S, Hakuno F, et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004;83(2):161-70
17. Brown J, Delaine C, Zaccheo OJ, et al. Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 2008;27(1):265-76
18. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007;4(10):591-602
19. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008;19(2):111-20
20. Oh SH, Lee OH, Schroeder CP, et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006;5(11):2685-95
21. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118(7):2609-19
22. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 2004;145(11):4976-84
23. Slomiany MG, Black LA, Kibbey MM, et al. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 2006;342(3):851-8
24. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000;14(6):783-94
25. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1-dependent mechanism. Oncogene 2007;26(13):1932-40
26. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001;21(15):5050-62
27. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11(8):3065-74
28. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5(10):2503-12
29. Ellis PM, Shepherd FA, Laurie SA, et al. NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer. J Thorac Oncol 2014;9(3):410-13
30. Belani CP, Dahlberg SE, Rudin CM, et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508). J Clin Oncol 2013;31(Suppl):abstract 7508
31. Chiappori A, Otterson G, Dowlati A, et al. Randomized Phase II study of single agent OSI-906, an oral, small molecule, tyrosine kinase inhibitor (TKI) of the insulin growth factor-1 receptor (IGF-1R) versus topotecan for the treatment of patients with relapsed small cell lung cancer (SCLC). J Thorac Oncol 2013;8(S2):S930. This the only ramdomized trial with a TKI IGF1-R in Small Cell Lung Cancer
32. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009;8(5):1095-105
33. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27(34):5800-7
34. Murakami H, Doi T, Yamamoto N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70(3):407-14
35. Lorigan P, Soria J-C, Stephenson AJ, et al. Safety and pharmacokinetics of first line AMG 479 or AMG 102 with platinum-based chemotherapy in extensive stage small cell lung cancer. Ann Oncol 2010;S8:viii149
36. Glisson B, Kazarnowicz A, Nackaerts K, et al. A multicenter, double-blind, placebo-controlled, randomized phase 2 study of ganitumab or rilotumumab with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC). J Thorac Oncol 2013;8(2):S220
37. Strosberg JR, Chan JA, Ryan DP, et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer 2013;20(3):383-90
38. Cohn AL, Tabernero J, Maurel J, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013;24(7):1777-85
39. Van Cutsem E, Nowara E, Swieboda-Sadjeli A, et al. A randomized, phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild type KRAS metastatic colorectal cancer: Primary and biomarker analyses. J Clin Onocl 2001;29(S):abstract3500
40. Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013;14(3):228-35
41. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012;23(11):2834-42
42. Ray-Coquard I, Haluska P, ÓReilly S, et al. A multicenter open label phase II study of the efficacy and safety of ganitumab, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor as second line therapy in patients with recurrent platinum sensitive ovarian cancer. J Clin Onocl 2013;31(s):abstract 5515
43. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012;30(15):1849-56
44. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29(34):4541-7
45. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29(34):4534-40
46. Pappo AS, Vassal G, Crowley JJ, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014. [Epub ahead of print]
47. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13(19):5834-40
48. Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014;15(2):191-200
49. Zucali PA, Petrini I, Lorenzi E, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010;116(20):4686-95